APPLICATION
NDA212905
TYPE
NDA
ORIGINAL APPROVAL
2023-07-21
LATEST ACTION
2023-07-21
ROUTE
TOPICAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
YCANTH · ReferencePrescription
CANTHARIDIN 0.7% · SOLUTION · TOPICAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.